Exact Sciences Corp (EXAS): Next-Year EPS Estimate 1889.27%
As of 2026-04-03, Exact Sciences Corp (EXAS) has a next-year EPS growth estimate of 1889.27%.
On 2026-03-25, analyst consensus for EXAS's next-year EPS growth shifted from 813.82% to 1889.27% — a positive change of 1075.45 percentage points. The revised estimate has been sustained across 20 subsequent trading sessions.
Current Snapshot
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- EPS growth next year
- 1889.27%
- EPS growth this year
- N/A
- EPS next quarter (est)
- -$0.19
- Last price
- $104.91
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-04-03 | 1889.27% | N/A | -$0.19 | $104.91 |
| 2026-04-01 | 1889.27% | N/A | N/A | $104.91 |
| 2026-04-01 | 1889.27% | N/A | N/A | $104.91 |
| 2026-04-01 | 1889.27% | N/A | N/A | $104.91 |
| 2026-04-01 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-31 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-31 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-31 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-30 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-30 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-30 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-29 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-29 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-27 | 1889.27% | N/A | N/A | N/A |
| 2026-03-26 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-26 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-26 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-25 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-25 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-25 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-24 | 813.82% | N/A | N/A | $104.91 |
| 2026-03-24 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-24 | 1889.27% | N/A | N/A | $104.91 |
| 2026-03-23 | 506.94% | N/A | N/A | $104.91 |
| 2026-03-20 | 460.30% | N/A | N/A | $104.91 |
| 2026-03-19 | 460.30% | N/A | N/A | $103.92 |
| 2026-03-18 | 460.30% | N/A | N/A | $103.75 |
| 2026-03-17 | 460.30% | N/A | N/A | $103.94 |
Recent News
- Abbott closes $23 billion deal to buy Madison-based Exact SciencesMilwaukee Journal Sentinel
- Abbott closes $23 billion deal to buy Madison-based Exact SciencesMilwaukee Journal Sentinel
- Abbott to close $21B Exact Sciences acquisition MondayMedTech Dive
- Abbott to close $21B Exact Sciences acquisition MondayMedTech Dive
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Exact Sciences Corp's next-year EPS growth estimate?▾
As of 2026-04-03, Exact Sciences Corp (EXAS) has a next-year EPS growth estimate of 1889.27%, based on analyst consensus.
When was the latest EPS estimate revision for EXAS?▾
The most recent revision occurred on 2026-03-25, when analysts adjusted the next-year EPS growth estimate from 813.82% to 1889.27%.
What sector and industry does Exact Sciences Corp belong to?▾
Exact Sciences Corp operates in the Healthcare sector, specifically the Diagnostics & Research industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. EXAS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Exact Sciences Corp (EXAS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports